Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

Mestas, E. Congenital cytomegalovirus. Adv. Neonatal Care 2016, 16, 60–65. [CrossRef] [PubMed]

Nagano, N.; Morioka, I. Congenital cytomegalovirus infection: Epidemiology, prediction, diagnosis, and emerging treatment

options for symptomatic infants. Expert Opin. Orphan Drugs 2020, 8, 1–9. [CrossRef]

Koyano, S.; Inoue, N.; Oka, A.; Moriuchi, H.; Asano, K.; Ito, Y.; Yamada, H.; Yoshikawa, T.; Suzutani, T.; Japanese Congenital

Cytomegalovirus Study Group. Screening for congenital cytomegalovirus infection using newborn urine samples collected on

filter paper: Feasibility and outcomes from a multicentre study. BMJ Open 2011, 1, e000118. [CrossRef]

Yamada, H.; Tanimura, K.; Fukushima, S.; Fujioka, K.; Deguchi, M.; Sasagawa, Y.; Tairaku, S.; Funakoshi, T.; Morioka, I. A cohort

study of the universal neonatal urine screening for congenital cytomegalovirus infection. J. Infect. Chemother. 2020, 26, 790–794.

[CrossRef]

Kimberlin, D.W.; Lin, C.Y.; Sánchez, P.J.; Demmler, G.J.; Dankner, W.; Shelton, M.; Jacobs, R.F.; Vaudry, W.; Pass, R.F.;

Kiell, J.M.; et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the

central nervous system: A randomized, controlled trial. J. Pediatr. 2003, 14, 16–25. [CrossRef]

Oliver, S.E.; Cloud, G.A.; Sánchez, P.J.; Demmler, G.J.; Dankner, W.; Shelton, M.; Jacobs, R.F.; Vaudry, W.; Pass, R.F.; Soong, S.J.; et al.

Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving

the central nervous system. J. Clin. Virol. 2009, 46, S22–S26. [CrossRef] [PubMed]

Kimberlin, D.W.; Jester, P.M.; Sánchez, P.J.; Ahmed, A.; Arav-Boger, R.; Michaels, M.G.; Ashouri, N.; Englund, J.A.; Estrada, B.;

Jacobs, R.F.; et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N. Engl. J. Med. 2015, 372, 933–943.

[CrossRef]

Luck, S.E.; Wieringa, J.W.; Blázquez-Gamero, D.; Henneke, P.; Schuster, K.; Butler, K.; Capretti, M.G.; Cilleruelo, M.J.; Curtis, N.;

Garofoli, F.; et al. Congenital cytomegalovirus: A European expert consensus statement on diagnosis and management. Pediatr.

Infect. Dis. J. 2017, 36, 1205–1213. [CrossRef]

Rawlinson, W.; Boppana, S.B.; Fowler, K.B.; Kimberlin, D.W.; Lazzarotto, T.; Alain, S.; Daly, K.; Doutré, S.; Gibson, L.;

Giles, M.L.; et al. Congenital cytomegalovirus infection in pregnancy and the neonate: Consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect. Dis. 2017, 17, e177–e188. [CrossRef]

Kawada, J.; Torii, Y.; Kawano, Y.; Suzuki, M.; Kamiya, Y.; Kotani, T.; Kikkawa, F.; Kimura, H.; Ito, Y. Viral load in children with

congenital cytomegalovirus infection identified on newborn hearing screening. J. Clin. Virol. 2015, 65, 41–45. [CrossRef]

Nishida, K.; Morioka, I.; Nakamachi, Y.; Kobayashi, Y.; Imanishi, T.; Kawano, S.; Iwatani, S.; Koda, T.; Deguchi, M.;

Tanimura, K.; et al. Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of

newborn urine screening and antiviral treatment. Brain Dev. 2016, 38, 209–216. [CrossRef] [PubMed]

Koyano, S.; Morioka, I.; Oka, A.; Moriuchi, H.; Asano, K.; Ito, Y.; Yoshikawa, T.; Yamada, H.; Suzutani, T.; Inoue, N.; et al.

Congenital cytomegalovirus in Japan: More than 2 year follow up of infected newborns. Pediatr. Int. 2018, 60, 57–62. [CrossRef]

[PubMed]

Ohyama, S.; Morioka, I.; Fukushima, S.; Yamana, K.; Nishida, K.; Iwatani, S.; Fujioka, K.; Matsumoto, H.; Imanishi, T.;

Nakamachi, Y.; et al. Efficacy of valganciclovir treatment depends on the severity of hearing dysfunction in symptomatic infants

with congenital cytomegalovirus infection. Int. J. Mol. Sci. 2019, 20, 1388. [CrossRef] [PubMed]

Fukushima, S.; Morioka, I.; Ohyama, S.; Nishida, K.; Iwatani, S.; Fujioka, K.; Mandai, T.; Matsumoto, H.; Nakamachi, Y.; Deguchi,

M.; et al. Prediction of poor neurological development in patients with symptomatic congenital cytomegalovirus diseases after

oral valganciclovir treatment. Brain Dev. 2019, 41, 743–750. [CrossRef] [PubMed]

Suganuma, E.; Sakata, H.; Adachi, N.; Asanuma, S.; Furuichi, M.; Uejima, Y.; Sato, S.; Abe, T.; Matsumoto, D.; Takahashi, R.; et al.

Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infection. J. Infect.

Chemother. 2021, 27, 185–191. [CrossRef]

Lombardi, G.; Garofoli, F.; Villani, P.; Tizzoni, M.; Angelini, M.; Cusato, M.; Bollani, L.; De Silvestri, A.; Regazzi, M.; Stronati, M.

Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur. J. Clin. Microbiol. Infect.

Dis. 2009, 28, 1465–1470. [CrossRef]

Bilavsky, E.; Shahar-Nissan, K.; Pardo, J.; Attias, J.; Amir, J. Hearing outcome of infants with congenital cytomegalovirus and

hearing impairment. Arch. Dis. Child. 2016, 101, 433–438. [CrossRef]

McCrary, H.; Sheng, X.; Greene, T.; Park, A. Long-term hearing outcomes of children with symptomatic congenital CMV treated

with valganciclovir. Int. J. Pediatr. Otorhinolaryngol. 2019, 118, 124–127. [CrossRef]

Ziv, L.; Yacobovich, J.; Pardo, J.; Yarden-Bilavsky, H.; Amir, J.; Osovsky, M.; Bilavsky, E. Hematologic adverse events associated

with prolonged valganciclovir treatment in congenital cytomegalovirus infection. Pediatr. Infect. Dis. J. 2019, 38, 127–130.

[CrossRef]

J. Clin. Med. 2022, 11, 3582

20.

21.

22.

23.

13 of 13

Turriziani Colonna, A.; Buonsenso, D.; Pata, D.; Salerno, G.; Chieffo, D.P.; Romeo, D.M.; Faccia, V.; Conti, G.; Molle, F.;

Baldascino, A.; et al. Long-term clinical, audiological, visual, neurocognitive and behavioral outcome in children with symptomatic and asymptomatic congenital cytomegalovirus infection treated with valganciclovir. Front. Med. 2020, 7, 268. [CrossRef]

Dorfman, L.; Amir, J.; Attias, J.; Bilavsky, E. Treatment of congenital cytomegalovirus beyond the neonatal period: An observational study. Eur. J. Pediatr. 2020, 179, 807–812. [CrossRef] [PubMed]

Morioka, I.; Kakei, Y.; Omori, T.; Nozu, K.; Fujioka, K.; Yoshikawa, T.; Moriuchi, H.; Ito, Y.; Oka, A. Efficacy and safety

of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: Study Protocol Clinical Trial (SPIRIT

Compliant). Medicine 2020, 99, e19765. [CrossRef] [PubMed]

Revello, M.; Gerna, G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Clin. Microbiol. Rev. 2002, 15, 680–715. [CrossRef] [PubMed]

...